JP2005525397A - 悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物 - Google Patents

悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物 Download PDF

Info

Publication number
JP2005525397A
JP2005525397A JP2003583443A JP2003583443A JP2005525397A JP 2005525397 A JP2005525397 A JP 2005525397A JP 2003583443 A JP2003583443 A JP 2003583443A JP 2003583443 A JP2003583443 A JP 2003583443A JP 2005525397 A JP2005525397 A JP 2005525397A
Authority
JP
Japan
Prior art keywords
tumors
tumor
salt
pharmaceutical composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003583443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525397A5 (enExample
Inventor
ボン リー、サン
ジン ヤン、ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29244880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005525397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2005525397A publication Critical patent/JP2005525397A/ja
Publication of JP2005525397A5 publication Critical patent/JP2005525397A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003583443A 2002-04-10 2002-04-10 悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物 Pending JP2005525397A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (2)

Publication Number Publication Date
JP2005525397A true JP2005525397A (ja) 2005-08-25
JP2005525397A5 JP2005525397A5 (enExample) 2008-06-26

Family

ID=29244880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583443A Pending JP2005525397A (ja) 2002-04-10 2002-04-10 悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物

Country Status (25)

Country Link
US (1) US20050106262A1 (enExample)
EP (2) EP1496918B1 (enExample)
JP (1) JP2005525397A (enExample)
CN (1) CN1298332C (enExample)
AP (1) AP2004003167A0 (enExample)
AU (2) AU2002253713B2 (enExample)
BG (1) BG66356B1 (enExample)
BR (1) BR0215689A (enExample)
CA (1) CA2481602C (enExample)
CY (1) CY1114422T1 (enExample)
DK (2) DK2042182T3 (enExample)
EC (1) ECSP045408A (enExample)
ES (2) ES2944907T3 (enExample)
FI (1) FI1496918T3 (enExample)
HU (1) HU230851B1 (enExample)
IL (2) IL164470A0 (enExample)
LT (1) LT1496918T (enExample)
MX (1) MXPA04009898A (enExample)
NO (1) NO335317B1 (enExample)
NZ (1) NZ536452A (enExample)
PT (2) PT1496918T (enExample)
RO (1) RO123269B1 (enExample)
TN (1) TNSN04198A1 (enExample)
UA (1) UA80426C2 (enExample)
WO (1) WO2003086424A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024488A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
RU2012108439A (ru) * 2009-09-18 2013-10-27 Коминокс, Инк. Способы лечения опухолей головного мозга
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
CN1119152C (zh) * 1998-08-02 2003-08-27 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Also Published As

Publication number Publication date
PT1496918T (pt) 2023-05-25
BG66356B1 (bg) 2013-09-30
CY1114422T1 (el) 2016-08-31
DK2042182T3 (da) 2013-08-26
DK1496918T3 (da) 2023-05-15
AU2008255139B2 (en) 2013-10-03
CN1625407A (zh) 2005-06-08
HUP0500199A2 (en) 2007-02-28
PT2042182E (pt) 2013-08-28
ES2944907T3 (es) 2023-06-27
EP1496918A1 (en) 2005-01-19
AP2004003167A0 (en) 2004-12-31
AU2002253713B2 (en) 2008-09-18
ECSP045408A (es) 2006-03-01
BR0215689A (pt) 2005-02-01
EP1496918B1 (en) 2023-02-08
NZ536452A (en) 2007-06-29
IL164470A (en) 2010-12-30
CN1298332C (zh) 2007-02-07
BG108932A (en) 2005-11-30
TNSN04198A1 (en) 2007-03-12
WO2003086424A1 (en) 2003-10-23
RO123269B1 (ro) 2011-05-30
UA80426C2 (en) 2007-09-25
CA2481602C (en) 2011-06-21
ES2425418T3 (es) 2013-10-15
US20050106262A1 (en) 2005-05-19
AU2002253713A1 (en) 2003-10-27
EP2042182A1 (en) 2009-04-01
CA2481602A1 (en) 2003-10-23
LT1496918T (lt) 2023-05-25
NO20044573L (no) 2004-10-22
NO335317B1 (no) 2014-11-10
MXPA04009898A (es) 2005-06-20
FI1496918T3 (fi) 2023-05-11
IL164470A0 (en) 2005-12-18
AU2008255139A1 (en) 2009-01-08
HUP0500199A3 (en) 2008-03-28
EP2042182B1 (en) 2013-05-22
HU230851B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
AU2008255139A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
US6656509B1 (en) Combination of selenium-containing compounds with cytostatics
Kosmidis et al. Chemotherapy in thymoma and myasthenia gravis
CN101386629B (zh) 以3-乙酰氧基-1,1-环丁烷二羧酸根为离去基团的水溶性Pt(II)抗癌配合物
RU2310460C2 (ru) Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия
US11166908B2 (en) Composition for preparing an anti-tumour agent and a method for preparing an anti-tumour agent on the basis of same
Hassan et al. Anti-hepatic cancer, antioxidant and anti-inflammatory effects of palladium (II) nano-complex
ZA200408114B (en) Pharmaceutical compositions comprising arsenite for the treatment of malignancy
US11866455B2 (en) Gold(III) complex, a conjugate of the gold(III) complex, a pharmaceutical composition comprising the gold(III) complex and uses and a process for preparing the gold(III) complex
FI91753C (fi) Menetelmä terapeuttisesti käyttökelpoisen telluuripitoisen kompleksin valmistamiseksi
Maier et al. The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human ovarian cancer cells
RU2277908C1 (ru) Водорастворимое средство, обладающее противовирусной активностью, на основе соединения серебра с цистином и способ его получения
OA12802A (en) Pharmaceutical composition comprising arsenite forthe treatment of malignancy.
RU2234923C2 (ru) Применение полигексаметиленгуанидинфосфата в качестве антидотного средства при интоксикациях тяжелыми металлами у экспериментальных животных
RU2392935C1 (ru) Способ сочетанного консервативного воздействия на злокачественные опухоли
EP0290169A2 (en) Diamineplatinum complexes with phosphonocarboxylate and substituted phosphonocarboxylate ligands as antitumor agents
Bai et al. Novel Oxovanadium Complex VO (hntdtsc)(NPIP): Anticancer Activity and Mechanism of Action on
CS250555B1 (cs) Protinádorový prostředek
JPS6176497A (ja) 白金錯体
Novello et al. Paclitaxel-based chemotherapy as second-line treatment in small cell lung cancer (SCLC)
Metintas et al. Carboplatin, ifosfamide, etoposide and interferon alpha-2A combination chemoimmunotherapy in the treatment of small cell lung carcinoma
CN103588687A (zh) 一种一价铜金属配合物及其制备方法和用途
Konishi et al. Carcinogenicity testing of food red no. 106 (acid red) in Fischer 344 rats
CN1785971A (zh) 安息香类贫铀促排剂、其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080424

RD05 Notification of revocation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7425

Effective date: 20080516

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080613

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20080916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091130

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120614